Pd L1 Expression - Cancer Science

Relevant Publications

Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment.

Issue Release: 2024

Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC.

Issue Release: 2024

Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer.

Issue Release: 2024

[Terminalia chebula water extract reduces joint inflammation by regulating cellular immunity in spleen cells of collagen-induced arthritis (CIA) rats through up-regulation of PD-1/PD-L1].

Issue Release: 2024

Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments.

Issue Release: 2024

Construction of a novel cancer-associated fibroblast-related signature to predict clinical outcome and immune response in cervical cancer.

Issue Release: 2024

Platelet PD-L1 inhibits storage-induced apoptosis by sustaining activation of the AKT signalling pathway.

Issue Release: 2024

PPARα phosphorylation regulates colorectal tumor immune escape.

Issue Release: 2024

Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.

Issue Release: 2024

Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer.

Issue Release: 2024

Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.

Issue Release: 2024

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.

Issue Release: 2024

Tumor-associated macrophages derived exosomes; from pathogenesis to therapeutic opportunities.

Issue Release: 2024

Immune profiling of mouse lung adenocarcinoma paraffin tissues using multiplex immunofluorescence panel: a pilot study.

Issue Release: 2024

Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial.

Issue Release: 2024

Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by F-BMS986-192 PET: pooled analysis of data from four solid tumor types.

Issue Release: 2024

Cancer stem cell-derived exosomes in CD8 T cell exhaustion.

Issue Release: 2024

ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.

Issue Release: 2024

5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC.

Issue Release: 2024

Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.

Issue Release: 2024

What are the barriers to accessing cancer testing?

Can miRNA-based therapies be used in cancer treatment?

How can enzyme expression be targeted for cancer therapy?

When Should You Worry About Dark Urine?

Why is MMSE Important in Cancer Care?

Can Biotechnology Help in Cancer Prevention?

What Are the Benefits of a Pharmaceutical Internship?

What Does Blinded Mean in Cancer Research?

When Should You Seek Medical Advice?

When is a Cancer Referral Necessary?

Pd L1 Expression - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics